鼻咽癌代谢亚型分类器指导个体化免疫治疗:III期CONTINUUM和DIPPER试验的生物标志物分析
本研究对III期CONTINUUM(发现队列)和DIPPER(验证队列)试验中407例局部晚期鼻咽癌患者的肿瘤样本进行RNA测序,通过代谢基因共识聚类确定三种代谢亚型并开发机器学习分类器。MS1亚型从抗PD-1联合放化疗中显著获益(3年EFS 90.2% vs 69.6%,HR 0.27),而MS2和MS3无显著获益,两队列汇总分析显示代谢亚型与治疗效果存在显著交互作用(P交互=0.0074)。
要点
- 基于代谢基因表达可区分鼻咽癌三种代谢亚型(MS1-MS3),各亚型免疫特征与预后不同。
- MS1亚型接受抗PD-1联合放化疗较单纯放化疗显著改善3年EFS(90.2% vs 69.6%,HR 0.27)。
- MS2与MS3亚型未从抗PD-1联合治疗中获得显著EFS获益。
核心结论
- 研究定义了可预测免疫治疗EFS获益的鼻咽癌代谢亚型,为局部晚期鼻咽癌个体化治疗决策提供了有前景的预测生物标志物。
研究设计与样本
- 对III期随机临床试验CONTINUUM(发现队列)和DIPPER(验证队列)共407例患者的肿瘤样本进行RNA测序。
- 在发现队列中基于代谢基因进行共识聚类确定亚型,并开发机器学习分类器应用于验证队列。
- 采用基因集富集分析表征各代谢亚型的生物学特征,临床终点为无事件生存期(EFS)。
主要发现
- 发现队列中鉴定出三种代谢亚型(MS1、MS2、MS3),具有不同的肿瘤内在与免疫特征及对化疗放疗(CRT)联合抗PD-1的差异EFS获益。
- MS1亚型抗PD-1联合CRT组较单纯CRT组3年EFS显著改善(90.2% vs 69.6%;HR 0.27,95%CI 0.11-0.67)。
- MS2亚型3年EFS为94.1% vs 93.8%,MS3亚型为75.0% vs 75.0%,均无显著生存获益。
- 验证队列中亚型特征得以保留,具有一致的预后和预测价值。
- 两队列汇总分析显示代谢亚型与治疗效果之间存在显著交互作用(P交互=0.0074)。
关键数值与推荐
- MS1亚型:抗PD-1联合CRT组3年EFS 90.2%,单纯CRT组69.6%,HR 0.27(95%CI 0.11-0.67)。
- MS2亚型:抗PD-1联合CRT组3年EFS 94.1%,单纯CRT组93.8%。
- MS3亚型:抗PD-1联合CRT组3年EFS 75.0%,单纯CRT组75.0%。
- 代谢亚型与治疗效果的交互作用P=0.0074。
临床怎么用
- 基于代谢基因表达的机器学习分类器可用于识别可能从抗PD-1联合放化疗中显著获益的MS1亚型鼻咽癌患者。
- MS2和MS3亚型患者可能无法从联合免疫治疗中获得显著EFS改善,提示需考虑其他治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Personalized immunotherapy strategies are urgently needed for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We aim to identify biomarkers predictive of immunotherapy benefits, using data from the phase III CONTINUUM (ClinicalTrials.gov identifier: NCT03700476) and DIPPER (ClinicalTrials.gov identifier: NCT03427827) randomized clinical trials. PATIENTS AND METHODS: Tumor samples from 407 patients in the CONTINUUM (discovery cohort) and DIPPER (validation cohort) trials were subjected to RNA sequencing. In the discovery cohort, metabolic gene-based consensus clustering was performed to determine subtypes. A machine learning-based classifier was subsequently developed in the discovery cohort and then applied to the validation cohort to assign metabolic subtypes. Gene set enrichment analyses were used to characterize the biological features of each metabolic subtype. The clinical end point was event-free survival (EFS). RESULTS: In the discovery cohort, three metabolic subtypes were identified with distinct tumor-intrinsic and immune features as well as differential EFS benefits from adding anti-PD-1 to chemoradiotherapy (CRT). Specifically, the MS1 subtype exhibited a significant improvement in 3-year EFS in the anti-PD-1 plus CRT arm compared with the CRT-alone arm (3-year EFS, 90.2% v 69.6%; hazard ratio, 0.27 [95% CI, 0.11 to 0.67]), whereas MS2 (3-year EFS, 94.1% v 93.8%) and MS3 subtypes (3-year EFS, 75.0% v 75.0%) derived no significant survival benefit. The subtype features were preserved in the validation cohort, with consistent prognostic and predictive value. A pooled analysis of both cohorts demonstrated the significant interaction between metabolic subtypes and the treatment effect (Pinteraction = 0.0074). CONCLUSION: In this biomarker study, we defined metabolic subtypes of NPC that predicted the EFS benefit from immunotherapy. This novel molecular classification provides a promising predictive biomarker for personalized treatment decision for patients with locoregionally advanced NPC.
引用
- Huang SW, Liang YL, Tao YL, et al. Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials. J Clin Oncol. 2026. PMID: 41791006. doi:10.1200/JCO-25-02111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。